首页> 外文期刊>Otology and neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology >Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear: Extended Dexamethasone Release From Silicone-based Implants
【24h】

Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear: Extended Dexamethasone Release From Silicone-based Implants

机译:跨卵窗植入物,一种向内耳给药的新方法:地塞米松从硅基植入物中的释放时间延长

获取原文
获取原文并翻译 | 示例
           

摘要

Hypothesis:The purpose of this study was to develop a new strategy to deliver drugs to the inner ear from dexamethasone (DXM)-loaded silicone implants and to evaluate the distribution of the drug in the cochlea with confocal microscopy.Background:Systemic drug administration for the treatment of inner ear disorders is tricky because of the blood-cochlear barrier, a difficult anatomical access, the small size of the cochlea, and can cause significant adverse effects. An effective way to overcome these obstacles is to administer drugs locally.Methods:In vitro, the drug release from DXM-loaded silicone-based thin films and tiny implants into artificial perilymph was thoroughly analyzed by high-performance liquid chromatography. In vivo, a silicone implant loaded with 10% DXM and 5% polyethylene glycol 400 was implanted next to the stapes's footplate of gerbils. Delivery of DXM into the inner ear was proved by confocal microscopy imaging of the whole cochlea and the organ of Corti.Results:The study showed a continuous and prolonged release during 90 days in vitro. This was confirmed by confocal microscopy that allowed detection of DXM by fluorescence labeling in the cell body of the hair cells for at least 30 days. Interestingly, fluorescence was already observed after 20 minutes of implantation, reached a climax at day 7, and could still be detected 30 days after implantation.Conclusions:Thus, we developed a new device for local corticosteroids delivery into the oval window with an extended drug release of DXM to the inner ear.
机译:假设:这项研究的目的是开发一种新策略,将药物从负载地塞米松(DXM)的硅胶植入内耳,并通过共聚焦显微镜评估药物在耳蜗中的分布。内耳疾病的治疗非常棘手,原因是血-耳蜗屏障,解剖学上的困难,耳蜗的尺寸小,并可能引起严重的不良反应。克服这些障碍的有效方法是局部给药。方法:在体外,通过高效液相色谱法彻底分析了载有DXM的有机硅基薄膜和微小植入物释放到人工外周淋巴液中的药物释放。在体内,将装有10%DXM和5%聚乙二醇400的有机硅植入物植入沙漏的骨足板旁边。共聚焦显微镜对整个耳蜗和Corti器官的显微成像证明了DXM可以进入内耳。结果:该研究表明在体外90天内持续且长时间释放。共聚焦显微镜证实了这一点,该共聚焦显微镜允许通过荧光标记在毛细胞的细胞体中检测DXM至少30天。有趣的是,在植入20分钟后就已经观察到荧光,在植入后第7天达到了高潮,并且在植入后30天仍然可以检测到。释放DXM到内耳。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号